A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers

Background Liquid biopsy for plasma circulating tumor DNA (ctDNA) next-generation sequencing (NGS) is commercially available and increasingly adopted in clinical practice despite a paucity of prospective data to support its use.